Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.53 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8876032 | 0.88 | SMN1; SMN2 (0.59) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL14172740 | 0.87 | KDM4E (0.60) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL7494720 | 0.85 | ALDH1A1 (0.44) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL1125257 | 0.85 | SRC (0.58) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL4598936 | 0.84 | TLR2 (0.55) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL3213856 | 0.83 | SRC (0.56) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL637742 | 0.83 | NPC1 (0.61) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL11290127 | 0.83 | SRC (0.50) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL11290130 | 0.83 | SRC (0.50) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL7403987 | 0.83 | NPC1 (0.47) | SRCNPC1RAB9ATLR2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257548-B1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-6455561-B1 | ADMINISTERING BENZOFURAN DERIVATIVE FOR THERAPY OF DISEASE STATE THAT IS CAPABLE OF BEING MODULATED BY INHIBITION OF PHOSPHODIESTERASE IV OR TUMOUR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2002-09-24 | — | — | US | disclosed |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-02-21 | — | — | US | disclosed |
| US-6331556-B2 | BENZOFURAN-4-CARBOXYLIC ACID AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITORS | DARWIN DISCOVERY, LTD. (GB) | 2001-12-18 | — | — | US | disclosed |
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | DARWIN DISCOVERY LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1054884-A1 | BENZOFURAN-4-CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| US-6066657-A | Benzofuran-4-carboxamides and their therapeutic use | DARWIN DISCOVERY, LTD. (GB) | 2000-05-23 | — | — | US | disclosed |
| WO-1999040085-A1 | BENZOFURAN-4-CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | CYP2F1, CYP11B2, CYP3A7 | SRC 1276/4885NPC1 42/4885RAB9A 771/4885 |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | EPX, MPO, PDE3B | SRC 2028/4885NPC1 1873/4885RAB9A 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.